On demand from #PROSCA24
Presenter: Dr. Ken Herrmann
Case discussion session: High-risk localised/locally advanced #ProstateCancer
TOPIC:Regional lymph node staging by PSMA-PET
buff.ly/4gaR6Kx
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Thank you Mirrors of Medicine & dear Colleagues
#PROSCA24 #BLADDR24 & #RENALC24
FINAL STATS with OVER 21 million impression on X
SHOUT OUT TO Our Ambassadors Specially
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@pgrivasmdphd.bsky.social
@achoud72.bsky.social
On demand #PROSCA24 🚨
Dr. Thomas Zilli
High-risk localised/locally advanced #prostatecancer
TOPIC: Combination of radiotherapy and systemic treatment for high-risk patients
buff.ly/3Z6ivq6
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Join Drs. Gillessen, Omlin, Castro, Zilli, Tombel & Turco as they discuss Advanced Prostate Cancer Consensus Conference 2024, presentation at #PROSCA24
#ProstateCancer
https://buff.ly/3B5902t
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@achoud72.bsky.social
@pgrivasmdphd.bsky.social
We Are @oncoalert.bsky.social 🚨
#PROSCA24
Thank you Mirrors of Medicine & dear Colleagues
#PROSCA24 #BLADDR24 & #RENALC24 have just concluded with OVER 20 million impression on X
SHOUT OUT TO Our Ambassadors
Specially
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@pgrivasmdphd.bsky.social
@achoud72.bsky.social
Day 2 #PROSCA24
Dr Elena Castro 🇪🇸
Management of castration-resistant prostate cancer (CRPC) patients
PARP inhibition in patients with CRPC: for everyone?
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day Two of #PROSCA24
Presenter: Dr Elena Castro
Management of castration-resistant prostate cancer (CRPC) patients
PARP inhibition in patients with CRPC: for everyone?
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Thanks @achoud72.bsky.social for the tips! Amazing meetings in Vienna: #PROSCA24 #BLADDR #RENALC @oncoalert.bsky.social
Learning from & interacting with friends/colleagues! @fredhutch.bsky.social @erplimackmd.bsky.social @jrgralow.bsky.social @glaucomflecken.bsky.social @johngoremd.bsky.social
Day One of #PROSCA24
Presenter: Dr. Ken Herrmann
Case discussion session: High-risk localised/locally advanced PCa
TOPIC: Regional lymph node staging by PSMA-PET
https://buff.ly/4gaR6Kx
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day One of #PROSCA24
Dr. Thomas Zilli
High-risk localised/locally advanced #prostatecancer
TOPIC: Combination of radiotherapy and systemic treatment for high-risk patients
https://buff.ly/3Z6ivq6
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day One of #PROSCA24
Presenter: Dr Bertrand Tombal
Biochemical recurrence following local therapy
TOPIC: Should we EMBARK or not? #ProstateCancer
https://buff.ly/3B5OVsK
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Great First Day of #PROSCA24
Congrats to our collaborators at Mirrors of Medicine on a Great day!
6Million Impressions on X w/ strong performances 🇺🇸🇬🇧🇮🇹🇹🇷🇨🇱🇪🇸🇭🇷& many more🌐
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
#PROSCA24
✨PSMA is the imaging choice in BCR
✨impact on clinical management ~60%
✨PPV 85-90%
✨different PSMA tracers with different detection rate
✨PROMISE registry to build monogram to predict survival: in BCR setting the nomogram had a strong correlation with survival
‼️for MDT: use PSMA11
#PROSCA24 livestream starting with ADT and cardiovascular risk in #ProstateCancer. Suma Konety
‼️ADT increases CV risk => development of metabolic syndrome
‼️Control of blood pressure and cholesterol is mandatory = high genomic diversity
@oncoalert.bsky.social @drnataliagandur.bsky.social
#EMBARK Trial - does this mean that salvage #radiotherapy is redundant?🤔
@oncoalert.bsky.social #PROSCA24
www.nejm.org/doi/full/10....
Day One of #PROSCA24
Presenter: Dr Bertrand Tombal
Biochemical recurrence following local therapy
EMBARK
in high-risk BCR requiring systemic therapy, adding enzalutamide to ADT improves MFS & OS
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Day One of #PROSCA24
Presenter: Dr Alfred Haidenberger
Biochemical recurrence following local therapy
Radiosurgery for Recurrent Prostate Cancer
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
#WhereisHoskin guides us through the evidence for salvage #radiotherapy for #prostatecancer Some things are clear
➡️ Early salvage
➡️ No benefit of dose escalation
Others not
➡️ Duration of ADT
➡️ Impact of nodal RT
@oncoalert.bsky.social #PROSCA24
Day One of #PROSCA24
Presenter: Dr Karolien Goffin
Biochemical recurrence following ocal therapy
PSMA-PET in BCR – what to expect?
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
After discussion 84% of the audience chose ‘NO’ #prosca24
Day One of #PROSCA24
Dr Thomas Zilli
High-risk localised/locally advanced PCa
Combination of radiotherapy and systemic treatment for high-risk patients: not one size fits all
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
Impressions up on 2023 - impact going from strength to strength - help us achieve more interaction for #PROSCA24
GREAT 1st DAY OF #PROSCA24
Currently going on in Vienna🇦🇹
Perfect way to follow up 2 Amazing meetings in #RENALC24 @ #BLADDR24 w/ OVER 10 million impressions on X ‼️
Kudos to Mirrors of Medicine
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social
#PROSCA24 on #BlueSky @oncoalert.bsky.social
Great talk on #PSMAPET - although it is superior for LN+ it is not infallible & isn't indicated in all patients @pgrivasmdphd.bsky.social welcome to #BlueSky
Should we rename Gleason 3+3 prostate cancer to premalignant? #prosca24
